Celina Dubin

Skin sensitivity may be best defined as self-reported intolerance to application of skincare products. It is commonly believed that individuals with darker skin are generally less sensitive, while those lighter skin are more sensitive. However, there is little objective data correlating sensitivity with skin type or with objective measures of sensitivity.

Co-founders Celina Dubin & Deniz Cataltepe's letter to the editor on the topic of: Hippocratic Oath and firearm violence prevention.

Having recently qualified as an MD, May 2022 this topic is even more pressing.

Originally appeared in:

https://chicago.suntimes.com/2022/7/16/23218484/future-south-shore-cultural-center-chicago-park-district-violence-medicine-letters

The East Harlem School At Exodus House Virtual Speaker Series featured Celina Dubin.

Available on Youtube:

https://www.youtube.com/watch?v=K5WBjeV3qXw

Frontal fibrosing alopecia was found to be limited to the scalp with inflammatory milieu linked to fibrosis and no systemic inflammation, suggesting possible treatment with immune-targeting therapeutics, according to a genetic analysis.

Genetic analysis: Frontal fibrosing alopecia limited to scalp with no systemic involvement.

Celina Dubin with the team-Jacob W.GlickmanMA

CelinaDubinBA YaelRenert-YuvalMD DanteDahabrehBA Grace W.Kimmel MD KelseyAuyeungBA Yeriel D Estrada BS GiselleSingerBS James G.KruegerMD, PhDbAna B.Pavel PhD EmmaGuttman-YasskyMD, PhD.

Although there is increased understanding of the alopecia areata (AA) pathogenesis based on studies in scalp tissues, little is known about its systemic profile.

Originally appeared as a research paper in Science Direct:

https://www.sciencedirect.com/science/article/abs/pii/S0190962220307593

AUTHORS: Benjamin Ungar. Jacob W Glickman. Alexandra K Golant. Celina Dubin. Olga Marushchak. Alyssa Gontzes. Daniela Mikhaylov. Giselle K Singer. Danielle Baum. Nancy Wei. Antonio Sanin. Diana Gruenstein. Mark G Lebwohl. Ana B Pavel. Emma Guttman-Yassky.

Background: In the SARS-CoV-2/COVID-19 pandemic, we need to understand the impact of immunomodulatory medications on COVID-19 symptom severity in patients with inflammatory diseases, including the type 2/Th2 polarized skin disease, atopic dermatitis (AD).

Originally appeared PubFacts:

https://www.pubfacts.com/detail/34737108/COVID-19-Symptoms-Are-Attenuated-in-Moderate-to-Severe-Atopic-Dermatitis-Patients-Treated-with-Dupil

Moderate-to-severe atopic dermatitis (AD) has been associated with significant disease burden and systemic abnormalities and often requires systemic treatments.

Currently, safe and effective oral systemic treatments for moderate-to-severe AD are not yet available.

ASN002 is an oral inhibitor of the Janus kinase/spleen tyrosine kinase signaling pathways, targeting several cytokine axes (T2/T22/T17/T1) and epidermal differentiation.

See the full test version: https://www.jacionline.org/article/S0091-6749(19)30961-3/fulltext

Our approach has the potential to facilitate future development of a personalized medicine approach in AD, and identify the best treatments for individual phenotypes, on the basis of immune and barrier profiles.

For the full version of the Study:

https://www.jacionline.org/article/S0091-6749(20)30039-7/fulltext

Chronic hand eczema (C.H.E) is a common and burdensome inflammatory skin condition seen in up to 10% of the population, more often in high-risk occupational workers.

Originally published in Pub Med:

https://pubmed.ncbi.nlm.nih.gov/33408476/